US009408858B2

(12) **United States Patent**
Bishop et al.

(10) **Patent No.: US 9,408,858 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **METHOD FOR TREATING SECONDARY HYPERPARATHYROIDISM IN CKD**

(71) Applicants: **OPKO RENAL, LLC**, Miami, FL (US); **Opko Ireland Global Holdings, Ltd.**, Grand Cayman (KY)

(72) Inventors: **Charles W. Bishop**, Miami Beach, FL (US); **Samir P. Tabash**, Whitby (CA); **Sammy A. Agudoawu**, Mississauga (CA); **Jay A. White**, Newmarket (CA); **Keith H. Crawford**, Highlands Ranch, CO (US); **Eric J. Messner**, Lake Forest, IL (US); **P. Martin Petkovich**, Kingston (CA)

(73) Assignees: **OPKO RENAL, LLC**, Miami, FL (US); **OPKO IRELAND GLOBAL HOLDINGS, LTD.**, Grand Cayman (KY)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/690,131**

(22) Filed: **Apr. 17, 2015**

(65) **Prior Publication Data**

US 2015/0216881 A1 Aug. 6, 2015

Related U.S. Application Data

(60) Continuation of application No. 14/305,863, filed on Jun. 16, 2014, which is a continuation of application No. 13/746,982, filed on Jan. 22, 2013, now Pat. No. 8,778,373, which is a division of application No. 12/109,983, filed on Apr. 25, 2008, now Pat. No. 8,361,488.

(60) Provisional application No. 60/913,853, filed on Apr. 25, 2007.

(51) **Int. Cl.**

A61K 31/59	(2006.01)
A61L 15/16	(2006.01)
A61F 13/02	(2006.01)
A61K 31/593	(2006.01)
A61K 9/48	(2006.01)
A61K 47/06	(2006.01)
A61K 47/10	(2006.01)
A61K 47/14	(2006.01)
A61K 47/44	(2006.01)
A61K 9/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/593*** (2013.01); ***A61K 9/0053*** (2013.01); ***A61K 9/4825*** (2013.01); ***A61K 9/4858*** (2013.01); ***A61K 9/4866*** (2013.01); ***A61K 31/59*** (2013.01); ***A61K 47/06*** (2013.01); ***A61K 47/10*** (2013.01); ***A61K 47/14*** (2013.01); ***A61K 47/44*** (2013.01); *A61K 9/0019* (2013.01)

(58) **Field of Classification Search**

USPC 424/422; 514/167

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,565,924	A	2/1971	DeLuca et al.
3,833,622	A	9/1974	Babcock et al.
3,880,894	A	4/1975	De Luca et al.
4,004,003	A	1/1977	Babcock et al.
4,230,701	A	10/1980	Holick et al.
4,335,120	A	6/1982	Holick et al.
4,448,721	A	5/1984	DeLuca et al.
4,555,364	A	11/1985	DeLuca et al.
4,668,517	A	5/1987	Weber et al.
4,684,524	A	8/1987	Eckenhoff et al.
4,695,591	A	9/1987	Hanna et al.
4,721,613	A	1/1988	Urquhart et al.
4,729,895	A	3/1988	Makino et al.
4,755,544	A	7/1988	Makino et al.
4,892,821	A	1/1990	Omura et al.
5,026,559	A	6/1991	Eichel et al.
5,160,742	A	11/1992	Mazer et al.
5,328,903	A	7/1994	Ishii et al.
5,342,626	A	8/1994	Winston, Jr. et al.
5,354,743	A	10/1994	Thys-Jacobs
5,403,831	A	4/1995	DeLuca et al.
5,431,917	A	7/1995	Yamamoto et al.
5,472,712	A	12/1995	Oshlack et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2241205	A1	7/1997
EP	0 227 836	A1	7/1987

(Continued)

OTHER PUBLICATIONS

"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease," National Kidney Foundation, *Am. J. Kidney Dis.*, 42 (Supplement 3):1-202 (2003).

Al-Aly, Z., "Changes in Serum 25-Hydroxyvitamin D and Plasma Intact PTH Levels Following Treatment with Ergocalciferol in Patients With CKD," Am. J. Kid. Dis., 50(1):59-68 (2007).

Andress, "Vitamin D in chronic kidney disease: A systematic role for selective vitamin D receptor activation," *Kidney Int.*, 69:33-43 (2006).

Arekat et al., "Dramatic Improvement of BMD Following Vitamin D Therapy in a Bone Marrow Transplant Recipient," *J. Clin. Densitometry*, 5:267-271 (2002).

(Continued)

Primary Examiner — Kathrien Cruz

(74) *Attorney, Agent, or Firm* — Marshall, Gerstein & Borun LLP

(57) **ABSTRACT**

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

22 Claims, 14 Drawing Sheets